Ocugen

OCGN · NASDAQ

$0.8125+$0.0252 (+3.20%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $0.7873

Latest news

Press releaseOct 14, 6:30 AM ETGlobe Newswire
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Press releaseOct 8, 2:49 PM ETPRNewswire
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Press releaseOct 6, 7:02 AM ETGlobe Newswire
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
NewsOct 6, 4:29 AM ET
Transcript: Ocugen Q2 2026 Earnings Conference Call
Press releaseSep 25, 7:02 AM ETGlobe Newswire
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
NewsSep 10, 9:43 AM ETHenry Khederian
What's Happening With Ocugen Stock Thursday?
NewsSep 9, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsSep 9, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseSep 1, 7:02 AM ETGlobe Newswire
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Press releaseAug 6, 7:02 AM ETGlobe Newswire
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
NewsJul 29, 7:13 AM ET
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
Press releaseJul 29, 7:01 AM ETGlobe Newswire
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
Press releaseJul 28, 4:01 PM ETGlobe Newswire
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
Press releaseJul 13, 7:02 AM ETGlobe Newswire
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Press releaseJul 1, 7:00 AM ETGlobe Newswire
Ocugen to Participate in Upcoming July Industry Conferences
NewsMay 5, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMay 5, 11:11 AM ET
Full Transcript: Ocugen Q1 2026 Earnings Call
NewsMay 5, 8:02 AM ETAvi Kapoor
GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
NewsMay 4, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseApr 29, 7:02 AM ETGlobe Newswire
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
Press releaseApr 10, 9:55 AM ETPRNewswire
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
NewsMar 24, 10:40 AM ETVandana Singh
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls
Press releaseMar 3, 9:00 AM ETPRNewswire
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
NewsJan 16, 12:07 PM ETHenry Khederian
Ocugen Stock Is Surging Today: What's Driving The Action?
NewsSep 19, 8:01 AM ET
Forecasting The Future: 4 Analyst Projections For Ocugen
NewsAug 4, 9:03 AM ET
Demystifying Ocugen: Insights From 5 Analyst Reviews
NewsJul 31, 2:01 PM ET
A Peek at Ocugen's Future Earnings
Press releaseJul 21, 7:30 AM ETGlobe Newswire
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
NewsJun 16, 10:58 AM ETHenry Khederian
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial
NewsMay 12, 8:02 AM ET
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts
NewsMay 8, 3:01 PM ET
A Look at Ocugen's Upcoming Earnings Report
NewsMar 6, 7:00 AM ET
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock
Press releaseFeb 24, 5:14 PM ETGlobe Newswire
Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)
NewsFeb 13, 7:00 AM ET
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts
NewsNov 11, 12:00 PM ET
Navigating 4 Analyst Ratings For Ocugen
NewsNov 7, 1:03 PM ET
A Preview Of Ocugen's Earnings
Press releaseSep 17, 8:00 AM ETBusiness Wire
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
Press releaseAug 20, 9:00 AM ETPRNewswire
Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading
NewsAug 1, 9:18 AM ETHenry Khederian
Why Ocugen (OCGN) Stock Is Falling

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Transcript: Ocugen Q2 2026 Earnings Conference Call

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

What's Happening With Ocugen Stock Thursday?

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen to Participate in Upcoming July Industry Conferences

12 Health Care Stocks Moving In Tuesday's Intraday Session

Full Transcript: Ocugen Q1 2026 Earnings Call

GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Earnings Scheduled For May 5, 2026

12 Health Care Stocks Moving In Monday's After-Market Session

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

Ocugen Stock Is Surging Today: What's Driving The Action?

Forecasting The Future: 4 Analyst Projections For Ocugen

Demystifying Ocugen: Insights From 5 Analyst Reviews

A Peek at Ocugen's Future Earnings

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

A Look at Ocugen's Upcoming Earnings Report

Beyond The Numbers: 5 Analysts Discuss Ocugen Stock

Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)

Expert Outlook: Ocugen Through The Eyes Of 4 Analysts

Navigating 4 Analyst Ratings For Ocugen

A Preview Of Ocugen's Earnings

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Why Ocugen (OCGN) Stock Is Falling